Intellia Therapeutics (NTLA) Free Cash Flow (2015 - 2026)
Intellia Therapeutics (NTLA) reported Free Cash Flow of -$117.4 million for Q1 2026, up 21.2% year-over-year from -$96.9 million in Q1 2025, and down 69.4% quarter-over-quarter from -$69.3 million in Q4 2025.
Intellia Therapeutics (NTLA) Free Cash Flow (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of Free Cash Flow data on file, last reported at -$117.4 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$117.4 million, up 21.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$363.2 million (up 3.23% YoY), and the FY2025 annual result was -$394.8 million, down 12.97% from the prior year.
- Free Cash Flow declined to -$117.4 million in Q1 2026 per NTLA's latest filing, from -$69.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$56.3 million in Q2 2024 and troughed at -$149.0 million in Q1 2025.
- A 5-year average of -$94.4 million and a median of -$93.0 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 40.49% in 2024, then tumbled 76.77% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$93.8 million in 2022, then grew by 0.8% to -$93.0 million in 2023, then grew by 12.96% to -$81.0 million in 2024, then climbed by 14.4% to -$69.3 million in 2025, then plunged by 69.4% to -$117.4 million in 2026.
- Business Quant data shows NTLA's Free Cash Flow at -$117.4 million in Q1 2026, -$69.3 million in Q4 2025, and -$76.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -117.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.43 Mn |
| Mar 31, 2026 | -117.43 Mn |
| Dec 31, 2025 | -69.32 Mn |
| Dec 31, 2025 | -69.32 Mn |
| Sep 30, 2025 | -76.90 Mn |
| Sep 30, 2025 | -76.90 Mn |
| Jun 30, 2025 | -99.54 Mn |
| Jun 30, 2025 | -99.54 Mn |
| Mar 31, 2025 | -149.01 Mn |
| Mar 31, 2025 | -149.01 Mn |
| Dec 31, 2024 | -80.98 Mn |
| Dec 31, 2024 | -80.98 Mn |
| Sep 30, 2024 | -89.00 Mn |
| Sep 30, 2024 | -89.00 Mn |
| Jun 30, 2024 | -56.31 Mn |
| Jun 30, 2024 | -56.31 Mn |
| Mar 31, 2024 | -123.17 Mn |
| Mar 31, 2024 | -123.17 Mn |
| Dec 31, 2023 | -93.03 Mn |
| Dec 31, 2023 | -93.03 Mn |